Fresenius Medical Care Management
Management criteria checks 3/4
Fresenius Medical Care's CEO is Helen Giza, appointed in Nov 2019, has a tenure of 5.92 years. total yearly compensation is €4.56M, comprised of 36.5% salary and 63.5% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth €1.09M. The average tenure of the management team and the board of directors is 3.8 years and 1.8 years respectively.
Key information
Helen Giza
Chief executive officer
€4.6m
Total compensation
| CEO salary percentage | 36.49% |
| CEO tenure | 5.9yrs |
| CEO ownership | 0.008% |
| Management average tenure | 3.8yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
Is Fresenius Medical Care (ETR:FME) A Risky Investment?
Sep 23
A Piece Of The Puzzle Missing From Fresenius Medical Care AG's (ETR:FME) Share Price
Aug 23Fresenius Medical Care AG Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next
Aug 08When Should You Buy Fresenius Medical Care AG (ETR:FME)?
Jul 07Fresenius Medical Care (ETR:FME) Could Be At Risk Of Shrinking As A Company
Jun 21Fresenius Medical Care AG's (ETR:FME) 29% Jump Shows Its Popularity With Investors
May 21We Discuss Why Fresenius Medical Care AG's (ETR:FME) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 16Earnings Update: Fresenius Medical Care AG (ETR:FME) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
May 09Fresenius Medical Care's (ETR:FME) Upcoming Dividend Will Be Larger Than Last Year's
Apr 09Fresenius Medical Care's (ETR:FME) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 14Why Fresenius Medical Care's (ETR:FME) Earnings Are Better Than They Seem
Mar 05Fresenius Medical Care (ETR:FME) Is Increasing Its Dividend To €1.44
Feb 28Is Now The Time To Look At Buying Fresenius Medical Care AG (ETR:FME)?
Feb 21What You Can Learn From Fresenius Medical Care AG's (ETR:FME) P/E
Feb 06Here's What's Concerning About Fresenius Medical Care's (ETR:FME) Returns On Capital
Dec 22What Is Fresenius Medical Care AG's (ETR:FME) Share Price Doing?
Nov 21
Strategic Innovations And Cost Efficiency Propel Growth In Global Healthcare Markets
Strategic focus on operational performance and cost savings initiatives is anticipated to enhance operating margins and improve earnings.Fresenius Medical Care AG (ETR:FME) Not Flying Under The Radar
Nov 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | €656m |
| Mar 31 2025 | n/a | n/a | €618m |
| Dec 31 2024 | €5m | €2m | €538m |
| Sep 30 2024 | n/a | n/a | €659m |
| Jun 30 2024 | n/a | n/a | €530m |
| Mar 31 2024 | n/a | n/a | €484m |
| Dec 31 2023 | €6m | €2m | €499m |
| Sep 30 2023 | n/a | n/a | €450m |
| Jun 30 2023 | n/a | n/a | €596m |
| Mar 31 2023 | n/a | n/a | €602m |
| Dec 31 2022 | €3m | €1m | €673m |
| Sep 30 2022 | n/a | n/a | €763m |
| Jun 30 2022 | n/a | n/a | €806m |
| Mar 31 2022 | n/a | n/a | €878m |
| Dec 31 2021 | €2m | €855k | €969m |
| Sep 30 2021 | n/a | n/a | €918m |
| Jun 30 2021 | n/a | n/a | €998m |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €2m | €855k | €1b |
| Sep 30 2020 | n/a | n/a | €1b |
| Jun 30 2020 | n/a | n/a | €1b |
| Mar 31 2020 | n/a | n/a | €1b |
| Dec 31 2019 | €2m | €108k | €1b |
Compensation vs Market: Helen's total compensation ($USD5.35M) is about average for companies of similar size in the German market ($USD5.34M).
Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.
CEO
Helen Giza (57 yo)
Ms. Helen Giza is Chief Executive Officer and Chair of the Management Board of Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & Co. KGAA from December 6, 2022. She serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chair of Management Board & CEO | 5.9yrs | €4.56m | 0.0082% € 1.1m | |
| CFO & Member of the Management Board | 2yrs | €2.52m | no data | |
| Global Chief Medical Officer & Member of Management Board | 5.8yrs | €2.76m | 0.0095% € 1.3m | |
| CEO of Care Enablement & Member of Management Board | 3.8yrs | €3.28m | 0.0045% € 589.7k | |
| CEO of Care Delivery & Member of Management Board | 1.8yrs | €3.72m | 0.014% € 1.8m | |
| Member of the Management Board | 1.3yrs | €1.38m | no data | |
| Executive Advisor for Regional Strategy | no data | €293.00k | no data | |
| Executive VP and Head of Investor Relations | no data | no data | no data | |
| Senior Vice President of Corporate Communications & Governmental Affairs | no data | no data | no data | |
| Senior Vice President of Research & Development | no data | no data | no data | |
| Senior Vice President of Manufacturing and Supply Chain Operations | no data | no data | no data | |
| Senior Vice President - Quality Management International | no data | no data | no data |
Experienced Management: FME's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Member of Supervisory Board | 1.9yrs | €245.00k | no data | |
| Chairman of the Supervisory Board | 2.3yrs | €509.00k | no data | |
| Independent Member of Supervisory Board | 1.9yrs | €297.00k | no data | |
| Independent Member of Supervisory Board | 4.4yrs | €213.00k | no data | |
| Employee Representative Deputy Chairwoman of the Supervisory Board | 1.8yrs | €320.00k | no data | |
| Member of Supervisory Board | 1.9yrs | €212.00k | no data | |
| Employee Representative Member of Supervisory Board | 1.8yrs | €189.00k | no data | |
| Employee Representative Member of the Supervisory Board | 1.8yrs | €181.00k | no data | |
| Employee Representative Member of the Supervisory Board | 1.8yrs | €187.00k | no data | |
| Employee representatives Member of the Supervisory Board | 1.8yrs | €189.00k | no data | |
| Employee representatives Member of the Supervisory Board | 1.8yrs | €161.00k | no data |
Experienced Board: FME's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 05:02 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fresenius Medical Care AG is covered by 60 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Brian Williams | Avondale Partners |
| Olav Zilian | Baader Helvea Equity Research |